Clinical Research Directory
Browse clinical research sites, groups, and studies.
CRP Apheresis in Infarct-Related Cardiogenic Shock
Sponsor: Leipzig Heart Science gGmbH
Summary
Cardiogenic shock complicating acute myocardial infarction remains associated with high short-term mortality despite guideline-directed therapy. Systemic inflammation, particularly elevated C-reactive protein (CRP), may contribute to ongoing myocardial injury and organ dysfunction. The CRP-SHOCK trial is an investigator-initiated, prospective, randomized, open-label, multicenter pilot study evaluating selective CRP apheresis as an adjunct to standard of care in patients with infarct-related cardiogenic shock. Patients are randomized to receive either standard therapy alone or standard therapy plus selective CRP apheresis using the PentraSorb®-CRP system. The primary objective is to assess the effect of CRP apheresis on the CLIP score at 66 ± 8 hours after randomization. Secondary objectives include clinical outcomes, inflammatory biomarkers, and safety endpoints.
Official title: Selective C-Reactive Protein Apheresis in Cardiogenic Shock Complicating Acute Myocardial Infarction (CRP-SHOCK Trial)
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-07-20
Completion Date
2027-10-31
Last Updated
2026-07-07
Healthy Volunteers
No
Interventions
Selective C-reactive protein apheresis (PentraSorb®-CRP)
Selective removal of circulating C-reactive protein using the PentraSorb®-CRP adsorber system as an adjunct to guideline-directed standard of care.
Standard of care
Guideline-directed medical and interventional treatment for cardiogenic shock complicating acute myocardial infarction.
Locations (1)
Heart Center Leipzig at University of Leipzig
Leipzig, Saxony, Germany